



## ERRATUM

# Erratum to Treatment strategies for patients with HER2-positive gastric cancer

Feixue Wang<sup>1</sup>, Yi Ba<sup>1,2</sup>

<sup>1</sup>Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin 300060, China; <sup>2</sup>Department of Medical Oncology, Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China

For the affiliation information, the affiliation for author Feixue Wang should be Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention

and Therapy, Tianjin Medical University, Tianjin 300060, China.

**Cite this article as:** Wang F, Ba Y. Erratum to Treatment strategies for patients with HER2-positive gastric cancer. *Cancer Biol Med.* 2024; 21: 267. doi: 10.20892/j.issn.2095-3941.2024.0070

---

Correspondence to: Yi Ba

E-mail: bayi@pumch.cn

ORCID ID: <https://orcid.org/0000-0003-0255-4376>.

Received February 22, 2024; accepted February 23, 2024.

Available at [www.cancerbiomed.org](http://www.cancerbiomed.org)

©2024 Cancer Biology & Medicine. Creative Commons

Attribution-NonCommercial 4.0 International License